Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9165211 | 0.92 | S1PR2 (0.51) | DNM1ADRB2ADRB1ADRB3TSHR | |
| SCHEMBL25761328 | 0.91 | CASR (0.49) | DNM1BCHEADRB2ADRB1ADRB3 | |
| SCHEMBL9165276 | 0.89 | DNM1 (0.48) | DNM1BCHEADRB2ADRB1ADRB3 | |
| SCHEMBL23964580 | 0.89 | MAPT (0.50) | DNM1BCHEADRB2ADRB1ADRB3 | |
| SCHEMBL2810250 | 0.85 | CA1 (0.60) | DNM1BCHEADRB2ADRB1ADRB3 | |
| SCHEMBL17005403 | 0.85 | CA1 (0.60) | DNM1BCHEADRB2ADRB1ADRB3 | |
| SCHEMBL24473808 | 0.85 | CA1 (0.60) | DNM1BCHEADRB2ADRB1ADRB3 | |
| SCHEMBL16728267 | 0.85 | TSHR (0.46) | DNM1BCHEADRB2ADRB1ADRB3 | |
| SCHEMBL16707869 | 0.84 | TSHR (0.47) | DNM1BCHEADRB2ADRB1ADRB3 | |
| SCHEMBL9168696 | 0.84 | DNM1 (0.49) | DNM1BCHEADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044113-B2 | curable in the absence of a polymerisation initiator; low viscosity, low cytotoxicity, and low solubility while having excellent mechanical properties such as low shrinkage and flexibility and which do not give rise to handling problems during manufacture and application | Dentsply International, Inc (US) | 2011-10-25 | — | — | US | disclosed |
| US-20080234404-A1 | curable in the absence of a polymerisation initiator; low viscosity, low cytotoxicity, and low solubility while having excellent mechanical properties such as low shrinkage and flexibility and which do not give rise to handling problems during manufacture and application | DENTSPLY DETREY GMBH (DE) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234404-A1 | curable in the absence of a polymerisation initiator; low viscosity, low cytotoxicity, and low solubility while having excellent mechanical properties such as low shrinkage and flexibility and which do not give rise to handling problems during manufacture and application | AAAS, PARG, PCNA | DNM1 2130/4885BCHE 2899/4885ADRB2 3441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.